Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949469 | 0.88 | FSCN1 (0.42) | FSCN1PPARGNTRK1HDAC1 | |
| SCHEMBL2945388 | 0.87 | PTGER1 (0.39) | ALKBH1PTGER1FSCN1PTGDR2PPARG | |
| SCHEMBL2945282 | 0.86 | FSCN1 (0.41) | ALKBH1FSCN1PTGDR2PPARGGPBAR1 | |
| SCHEMBL2946889 | 0.86 | FSCN1 (0.42) | ALKBH1FSCN1PTGDR2PPARG | |
| SCHEMBL2945342 | 0.86 | PTGER1 (0.42) | ALKBH1PTGER1FSCN1PTGDR2PPARG | |
| SCHEMBL2943369 | 0.86 | CNR2 (0.43) | PTGER1FSCN1PTGDR2 | |
| SCHEMBL4806357 | 0.84 | HTR6 (0.45) | FSCN1 | |
| SCHEMBL4805917 | 0.83 | PTGER1 (0.40) | ALKBH1PTGER1FSCN1PTGDR2PPARG | |
| SCHEMBL5527630 | 0.82 | DDR1 (0.36) | ALKBH1PTGER1FSCN1PTGDR2PPARG | |
| SCHEMBL4932344 | 0.80 | HDAC6 (0.42) | FSCN1PTGDR2PPARGNTRK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558611-B1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
| US-7368571-B2 | HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use | PFIZER INC (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7135482-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1558611-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004039803-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | IMPDH1, POLA1, POLB | ALKBH1 948/4885PTGER1 550/4885FSCN1 4789/4885 |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | ALKBH1 907/4885PTGER1 891/4885FSCN1 4800/4885 |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | ALKBH1 1206/4885PTGER1 888/4885FSCN1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.